吉斯凯的实验性癌症药物Mo-Rez显示出有前途的早期结果. GSK's experimental cancer drug Mo-Rez shows promising early results.

吉斯凯公司报告了其实验性癌症药物Mo-Rez的早期结果,显示瘤在62%的卵巢癌患者和67%的子宫内膜癌患者中显著缩小. GSK reported promising early results for its experimental cancer drug Mo-Rez, showing significant tumor shrinkage in 62% of ovarian cancer patients and 67% of endometrial cancer patients. 这种抗体与药物联合剂是从中国的汉索制药公司获得的, 针对癌细胞对健康组织的影响很小. The antibody-drug conjugate, acquired from China's Hansoh Pharma, targets cancer cells with minimal impact on healthy tissue. 吉斯基公司计划扩大开发, 并将其视为新任首席执行官卢克·米尔斯的潜在巨头药物. GSK plans to expand development and views it as a potential blockbuster drug under new CEO Luke Miels.